SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kwality Pharma - Quaterly Results

13 Feb 2026 Evaluate
The sales surged to Rs. 1234.45 millions, up 46.25% for the December 2025 quarter as against Rs. 844.07 millions during the corresponding quarter previous year.Profit for the quarter ended December 2025 rises by 87.45% to Rs. 160.06  millions from Rs. 85.39 millions.Operating profit for the quarter ended December 2025 rose to 304.81 millions as compared to 181.60 millions of corresponding quarter ended December 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 1234.45 844.07 46.25 3462.37 2545.20 36.04 3701.97 3071.72 20.52
Other Income 5.28 6.55 -19.39 18.01 11.55 55.93 19.20 18.30 4.92
PBIDT 304.81 181.60 67.85 812.90 556.98 45.95 823.64 684.63 20.30
Interest 24.82 22.01 12.77 80.84 73.86 9.45 98.78 103.87 -4.90
PBDT 271.70 159.59 70.25 723.77 483.12 49.81 724.86 509.77 42.19
Depreciation 48.18 45.48 5.94 145.34 131.80 10.27 182.58 195.11 -6.42
PBT 223.52 114.11 95.88 578.43 351.32 64.64 542.28 314.66 72.34
TAX 63.46 28.72 120.96 157.89 97.42 62.07 143.38 74.83 91.61
Deferred Tax 0.25 0.03 733.33 9.58 -0.03 -32033.33 -15.89 -4.37 263.62
PAT 160.06 85.39 87.45 420.54 253.90 65.63 398.90 239.83 66.33
Equity 103.76 103.76 0.00 103.76 103.76 0.00 103.76 103.76 0.00
PBIDTM(%) 24.69 21.51 14.77 23.48 21.88 7.29 22.25 22.29 -0.18

Kwality Pharma Share Price

1664.30 -82.70 (-4.73%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×